Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency
摘要:
Starting with our previously described(20) class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase 1 clinical trials.
There are provided compounds of the formula
wherein X, Y, R
1
, R
2
, R
3
, R
3
, R
4
, R
5
, R
6
and R
7
are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
[EN] SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRIMIDINYL-AMINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE LA PROTÉINE KINASE
申请人:SCRIPPS RESEARCH INST
公开号:WO2009032861A1
公开(公告)日:2009-03-12
The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.
Piperidine amides as modulators of chemo kine receptor activity
申请人:——
公开号:US20020156102A1
公开(公告)日:2002-10-24
The present application describes modulators of CCR3 of formula (I):
1
or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
本申请描述了公式(I)的CCR3调节剂或其药用盐形式,可用于预防哮喘和其他过敏性疾病。
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
申请人:Bristol-Myers Squibb Pharma Co.
公开号:US06525069B1
公开(公告)日:2003-02-25
The present application describes modulators of CCR3 of formula (I):
or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
There are provided compounds of the formula (I) wherein X, Y, R1, R2, R3, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.